Vera Therapeutics Stock Today

VERA Stock  USD 48.09  0.95  1.94%   

Performance

11 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 8

 
High
 
Low
Low
Vera Therapeutics is trading at 48.09 as of the 8th of November 2024, a 1.94 percent decrease since the beginning of the trading day. The stock's open price was 49.04. Vera Therapeutics has only a 8 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. Equity ratings for Vera Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of November 2023 and ending today, the 8th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
14th of May 2021
Category
Healthcare
Classification
Health Care
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. The company has 61.97 M outstanding shares of which 6.19 M shares are at this time shorted by private and institutional investors with about 8.96 trading days to cover. More on Vera Therapeutics

Moving against Vera Stock

  0.58VALN Valneva SE ADRPairCorr
  0.5DRMA Dermata TherapeuticsPairCorr
  0.46VCNX Vaccinex Earnings Call This WeekPairCorr
  0.41ME 23Andme HoldingPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Vera Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities13 M22.3 M
Way Down
Slightly volatile
Non Current Liabilities Total43.1 M51.6 M
Fairly Down
Very volatile
Total Assets99.1 M175.5 M
Way Down
Slightly volatile
Total Current Assets95 M165.5 M
Way Down
Slightly volatile
Debt Levels
Vera Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vera Therapeutics' financial leverage. It provides some insight into what part of Vera Therapeutics' total assets is financed by creditors.
Liquidity
Vera Therapeutics currently holds 53.71 M in liabilities with Debt to Equity (D/E) ratio of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vera Therapeutics has a current ratio of 8.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vera Therapeutics' use of debt, we should always consider it together with its cash and equity.

Investments

(42.32 Million)
Vera Therapeutics (VERA) is traded on NASDAQ Exchange in USA. It is located in 8000 Marina Boulevard, Brisbane, CA, United States, 94005 and employs 72 people. Vera Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.04 B. Vera Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.97 M outstanding shares of which 6.19 M shares are at this time shorted by private and institutional investors with about 8.96 trading days to cover. Vera Therapeutics currently holds about 131.93 M in cash with (92.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.86.
Check Vera Therapeutics Probability Of Bankruptcy
Ownership Allocation
Vera Therapeutics shows a total of 61.97 Million outstanding shares. The majority of Vera Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vera Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vera Therapeutics. Please pay attention to any change in the institutional holdings of Vera Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that roughly two million five hundred eighty-four thousand one hundred seventy invesors are currently shorting Vera Therapeutics expressing very little confidence in its future performance.
Check Vera Ownership Details

Vera Stock Institutional Holders

InstituionRecorded OnShares
Kynam Capital Management, Lp2024-06-30
1.5 M
Samlyn Capital, Llc2024-06-30
1.2 M
Adage Capital Partners Gp Llc2024-06-30
1.1 M
First Light Asset Management, Llc2024-06-30
M
Geode Capital Management, Llc2024-06-30
984.4 K
Woodline Partners Lp2024-06-30
948.9 K
Artal Group S A2024-06-30
916 K
Goldman Sachs Group Inc2024-06-30
784.6 K
Readystate Asset Management Lp2024-06-30
772.7 K
Venbio Select Advisor Llc2024-06-30
4.3 M
T. Rowe Price Associates, Inc.2024-06-30
3.6 M
View Vera Therapeutics Diagnostics

Vera Therapeutics Historical Income Statement

At present, Vera Therapeutics' Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 7.3 M, whereas Depreciation And Amortization is projected to grow to (3.9 M). View More Fundamentals

Vera Stock Against Markets

Vera Therapeutics Corporate Management

Tad ThomasSr ManufacturingProfile
Lauren MBAChief OfficerProfile
Marshall MDPresident, FounderProfile
Julien JDSenior LegalProfile
Joanne CurleyChief OfficerProfile
Kerry MDSenior AffairsProfile
Joseph MBASenior OfficerProfile
When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.19)
Return On Assets
(0.25)
Return On Equity
(0.46)
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.